The Australian researchers conducting this study used data from the Long-term Intervention
with Pravastatin in Ischaemic Disease (LIPID) study conducted in the early 1990s to estimate …

Objective: To measure the cost‐effectiveness of cholesterol‐lowering therapy with
pravastatin in patients with established ischaemic heart disease and average baseline …

The Long Term Pravastatin in Ischaemic Disease (LIPID) Study was conducted at 87 centres
in Australia and New Zealand. The primary objective was to test the hypothesis that lowering …

Aims To assess the effects of pravastatin on all-cause mortality and cause-specific mortality
and to compare the effects for patients with prior coronary heart disease with those for …

Background In patients with coronary heart disease and a broad range of cholesterol levels,
cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality …

Aim To evaluate the efficacy and safety of pravastatin 20mg at night, versus placebo, in
combination with dietary, smoking cessation, and other lifestyle advice in general practice …

Pravastatin reduces all-cause mortality and is cost effective among patients with established
ischaemic heart disorders and 'average'cholesterol levels, say researchers from Australia …

Andrew M. Tonkin National Heart Foundation of Australia, West Melbourne, Victoria, and the
LIPID Study Group, AustraliaDavid Hunt Royal Melbourne Hospital, Melbourne, Victoria, and …

OBJECTIVES The purpose of the study was to assess the effect of lipid reduction with
pravastatin on hospital admissions in middle-aged men with hypercholesterolemia in the …

Despite benefits of cholesterol lowering treatment seen in earlier trials, treatment effect on
mortality in patients with relatively normal cholesterol levels has remained uncertain. The …